These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36714975)

  • 21. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
    Lang FF; Miller DC; Koslow M; Newcomb EW
    J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas.
    Newcomb EW; Alonso M; Sung T; Miller DC
    Hum Pathol; 2000 Jan; 31(1):115-9. PubMed ID: 10665922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metallothionein Genes are Highly Expressed in Malignant Astrocytomas and Associated with Patient Survival.
    Masiulionytė B; Valiulytė I; Tamašauskas A; Skiriutė D
    Sci Rep; 2019 Apr; 9(1):5406. PubMed ID: 30932010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
    Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
    Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma.
    Tanizaki Y; Sato Y; Oka H; Utsuki S; Kondo K; Miyajima Y; Nagashio R; Fujii K
    Pathol Int; 2006 Sep; 56(9):510-5. PubMed ID: 16930331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas.
    Tomaselli S; Galeano F; Massimi L; Di Rocco C; Lauriola L; Mastronuzzi A; Locatelli F; Gallo A
    BMC Cancer; 2013 May; 13():255. PubMed ID: 23697632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers.
    Ichimura K; Narita Y; Hawkins CE
    Acta Neuropathol; 2015 Jun; 129(6):789-808. PubMed ID: 25975377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
    Ohgaki H; Kleihues P
    J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of p53 mutations during astrocytoma tumorigenesis.
    del Arco A; García J; Arribas C; Barrio R; Blázquez MG; Izquierdo JM; Izquierdo M
    Hum Mol Genet; 1993 Oct; 2(10):1687-90. PubMed ID: 8268922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort.
    Pollack IF; Finkelstein SD; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Finlay JL; Sposto R;
    Cancer Res; 2001 Oct; 61(20):7404-7. PubMed ID: 11606370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MIB-1 and p53 immunocytochemistry for differentiating pilocytic astrocytomas and astrocytomas from anaplastic astrocytomas and glioblastomas in children and young adults.
    Matsumoto T; Fujii T; Yabe M; Oka K; Hoshi T; Sato K
    Histopathology; 1998 Nov; 33(5):446-52. PubMed ID: 9839169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TIMP-4 and CD63: new prognostic biomarkers in human astrocytomas.
    Rorive S; Lopez XM; Maris C; Trepant AL; Sauvage S; Sadeghi N; Roland I; Decaestecker C; Salmon I
    Mod Pathol; 2010 Oct; 23(10):1418-28. PubMed ID: 20693981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors.
    Rathore A; Kamarajan P; Mathur M; Sinha S; Sarkar C
    Pathol Oncol Res; 1999; 5(1):21-7. PubMed ID: 10079373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of EGFR signaling from pilocytic astrocytomas to glioblastomas.
    Carvalho PO; Uno M; Oba-Shinjo SM; Rosemberg S; Wakamatsu A; da Silva CC; Teixeira MJ; Marie SK
    Int J Biol Markers; 2014 Jun; 29(2):e120-8. PubMed ID: 24170555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations.
    Liu XY; Gerges N; Korshunov A; Sabha N; Khuong-Quang DA; Fontebasso AM; Fleming A; Hadjadj D; Schwartzentruber J; Majewski J; Dong Z; Siegel P; Albrecht S; Croul S; Jones DT; Kool M; Tonjes M; Reifenberger G; Faury D; Zadeh G; Pfister S; Jabado N
    Acta Neuropathol; 2012 Nov; 124(5):615-25. PubMed ID: 22886134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
    Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
    Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression patterns of Wnt signaling component, secreted frizzled‑related protein 3 in astrocytoma and glioblastoma.
    Pećina-Šlaus N; Kafka A; Varošanec AM; Marković L; Krsnik Ž; Njirić N; Mrak G
    Mol Med Rep; 2016 May; 13(5):4245-51. PubMed ID: 27035837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation.
    Mott RT; Turner KC; Bigner DD; McLendon RE
    J Neurosurg; 2008 Feb; 108(2):330-5. PubMed ID: 18240930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.
    Ramachandran RK; Sørensen MD; Aaberg-Jessen C; Hermansen SK; Kristensen BW
    PLoS One; 2017; 12(2):e0172234. PubMed ID: 28234925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.